WELCOME TO The Biotechnology REPORT
Center for Human Genetics
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Sequence Bio | April 08, 2022
Sequence Bio, a Newfoundland and Labrador-based discovery biology company, announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio's proprietary discovery platform to identify novel dermatologic drug targets. Under the terms of the three year agreement, Sequence Bio will perform multi-omic analyses of samples from powered discovery cohorts across multiple dermatologic indications. LEO Pharma will leverage insi...
Cellectis Inc. | February 19, 2022
Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. , a majority-owned subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock.
Cell and Gene Therapy
Intravacc | September 12, 2022
Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable preclinical and toxicology data for Avacc 10®, the company's SARS-CoV-2 intranasal candidate vaccine. These results demonstrate a reduction in upper respiratory tract viral load, broad cross protection against circulating variants of concern. and a good safety profile, allowing progression towards a phase I clinical study.
Sotira | November 25, 2020
Sotira, the Phoenix based biotech organization, is pleased to report the successful finish of the second period of pre-clinical testing for its COVID-19 therapeutic and vaccine-alternative, KEPTIDE™ COVID, confirming that this cutting-edge molecular therapy completely prevented of SARS-CoV2 in the lungs and kidney. These mice are viewed as a best quality level preclinical model to study COVID-19 on the grounds that the mice express human ACE2, the receptor utilized by the virus to gain ent...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE